Ipamorelin Peptide: Status, Evidence and Sellers

Ipamorelin is a synthetic five-amino-acid peptide that acts selectively at the ghrelin receptor, asking the pituitary for growth hormone. Among the early secretagogues it stood out for producing real GH pulses while leaving cortisol, prolactin and ACTH largely alone. That selectivity is what sets it apart from the older releasing peptides, GHRP-2 and GHRP-6 among them [1].

It holds no FDA approval for anything, and FDA lists it among bulk substances whose compounding may present significant safety risks. What it gets prescribed for off-label is body composition, recovery and sleep, very often paired with a GHRH analog, usually CJC-1295 or else sermorelin.

The evidence is overwhelmingly preclinical (animals and cell work), with exactly one published human randomized trial, and that trial measured gut motility rather than anything to do with body composition or aging. Evidence grade C.

It copies ghrelin, the hormone behind appetite regulation, at the GHSR-1a receptors sitting on pituitary somatotrophs. That triggers a Gq/11-coupled cascade, raises calcium inside the cell and pushes growth hormone out in a pulse [1]. Its selectivity is the defining feature: at the doses used, it does not meaningfully drive ACTH or cortisol, where GHRP-2 and GHRP-6 reliably do [1].

Pairing it with a GHRH analog works because the two hit different receptors, and activating both produces larger pulses than either manages alone. Half-life in humans runs about two hours [2], which is what supports dosing anywhere from once to three times a day in practice.

The human foundation is pharmacokinetic rather than clinical. A study in healthy volunteers characterized the dose-response relationship and showed GH release that reproduced across dosing intervals [2]. That establishes that the peptide works as described mechanically in people. The study was not built to measure lean mass, fat loss or anything else a patient would care about.

One human randomized trial with a clinical endpoint has been published: a 2014 proof-of-concept study in 117 patients recovering from bowel resection, testing it against postoperative ileus. Time to a first tolerated meal was 25.3 hours on ipamorelin against 32.6 on placebo, a difference that was not statistically significant [3]. That is a gut-motility result in surgical patients, a long way from the body-composition claims made for it in wellness settings.

Animal work supplies the mechanism without supplying the outcomes. In adult rats it offset glucocorticoid-driven reductions in bone formation, consistent with GH acting anabolically [4]. A rodent model of the same post-surgical gut problem confirmed prokinetic effects that scaled with dose [5]. Among steroid-treated rats it improved nitrogen balance and lowered urea synthesis, which points toward protein anabolism [6]. A 2024 ferret study found it reduced weight loss caused by cisplatin, suggesting possible use in cachexia [7].

What no controlled human trial has measured, as a primary endpoint, is lean mass gained, fat lost, sleep architecture or bone density. Every claim about those in healthy adults is extrapolation from growth hormone physiology plus clinical anecdote.

No dose of ipamorelin is approved for any use. Two human studies set out the doses that have been tested. A 1999 study in healthy men gave single 15-minute intravenous infusions at five rising levels to model how the body handles it, and found a short half-life of about two hours [2]. A 2014 trial in patients recovering from bowel surgery gave 0.03 mg per kg intravenously twice a day for up to seven days and found it well tolerated [3].

Neither study used injections under the skin for sleep, recovery or body composition, which is how it is sold. Compounding prescribers' schedules are not drawn from a trial, so this page does not print one. Oral forms have not been studied at all.

Compounding pharmacies are the only US source, and they do not operate under the manufacturing standards approved drugs are held to, so potency, sterility and purity vary between them. The clean hormonal profile, with little cortisol or prolactin stimulation, is the main reason clinicians reach for this over the older secretagogues [1].

Side effects reported from clinical use and anecdote are mild: reactions at the injection site, temporary fluid retention, headache, flushing. FDA's compounding safety listing is less reassuring: it cites a published study in which ipamorelin given intravenously for gut motility was followed by serious adverse events, including death. Long-term human safety data are essentially nonexistent, because no study has followed anyone on it beyond a few weeks. As with anything that raises GH and IGF-1, caution applies to anyone with current or previous malignancy. It should not be used in pregnancy. All use for body composition or aging in healthy adults is off-label.